EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Multicenter Retrospective Study of Efficacy of Systemic Therapy in Patients with Neuroendocrine Tumor Grade 3 (JOSC-2001)

Hiroyuki Okuyama, Taro Shibuki, Naohiro Okano, Takuro Mizukami, Hiroaki Yanagimoto, Mao Okada, Emiri Kita, Noritoshi Kobayashi, Satoshi Kobayashi, Takaaki Furukawa, Hiroyuki Asama, Hidetaka Tsumura und 16 weitere

Neuroendocrinology · 2025

DOI: 10.1159/000548614 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Neuroendocrinology, 2025. Verfasst von Hiroyuki Okuyama und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Kagawa University Hospital, Miki, Japan, okuyama.hiroyuki@kagawa-u.ac.jp. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Pancreatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neuroendocrine tumor G3 (NET G3) is a new category introduced in the WHO 2017 classification. Accordingly, evidence regarding chemotherapy for NET G3 is limited. A multicenter, retrospective analysis was performed to evaluate the outcomes of systemic therapy for NET G3 and to identify the optimal regimens.

Methods

Patient demographic and treatment outcome data were retrospectively collected for 73 patients with pathologically diagnosed NET G3 who started chemotherapy at participating institutions between January 2011 and December 2019, excluding those who were ineligible by central pathological review. The chemotherapy regimens used and their efficacies were evaluated.

Results

Of the 73 patients, 47 had pancreatic NETs, 10 had gastrointestinal NETs, and 16 had NETs at other sites. Central pathological review was performed for 44 patients, with a concordance rate of 95%. Initial treatment regimens included NET-based treatment (somatostatin analog, molecular-targeted agent, cytotoxic chemotherapy such as streptozocin and temozolomide) for 37 patients, neuroendocrine carcinoma (NEC)-based treatment (platinum-containing chemotherapy) for 32 patients, and other regimens for 2 patients. There were no significant differences in progression-free survival (PFS) or overall survival (OS) between patients receiving NET-based and NEC-based treatment or among the individual treatment regimens. However, the response rate (RR) was higher for NET-based cytotoxic chemotherapy (50%) compared with NEC-based treatment (16%), suggesting greater efficacy of NET-based cytotoxic chemotherapy.

Conclusions

Although no significant difference in PFS or OS was found among the chemotherapy regimens for NET G3, RR was notably higher for NET-based cytotoxic chemotherapy than for NEC-based treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsPancreatic NeoplasmsGastrointestinal NeoplasmsHumansRetrospective StudiesFemaleMaleMiddle AgedAgedAdultNeoplasm GradingTreatment OutcomeAged, 80 and over

Stichwörter der Autor:innen

ChemotherapyNeuroendocrine tumor G3Systemic therapy

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Oncology, Kagawa University Hospital, Miki, Japan, okuyama.hiroyuki@kagawa-u.ac.jp.
  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.
  • Department of Medical Oncology, NTT Medical Center Tokyo, Tokyo, Japan.
  • Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.

Zitieren

APA

Okuyama, H., Shibuki, T., Okano, N., Mizukami, T., Yanagimoto, H., Okada, M., Kita, E., Kobayashi, N., Kobayashi, S., Furukawa, T., Asama, H., Tsumura, H., Kamata, K., Umemoto, K., Hamamoto, Y., Suzuki, Y., Horiguchi, S., Naganuma, A., Asagi, A., …, & Ikeda, M. (2025). Multicenter Retrospective Study of Efficacy of Systemic Therapy in Patients with Neuroendocrine Tumor Grade 3 (JOSC-2001). Neuroendocrinology. https://doi.org/10.1159/000548614

Vancouver

Okuyama H, Shibuki T, Okano N, Mizukami T, Yanagimoto H, Okada M, et al. Multicenter Retrospective Study of Efficacy of Systemic Therapy in Patients with Neuroendocrine Tumor Grade 3 (JOSC-2001). Neuroendocrinology. 2025. doi:10.1159/000548614

BibTeX
@article{Okuyama2025,
  author = {Okuyama, Hiroyuki and Shibuki, Taro and Okano, Naohiro and Mizukami, Takuro and Yanagimoto, Hiroaki and Okada, Mao and Kita, Emiri and Kobayashi, Noritoshi and Kobayashi, Satoshi and Furukawa, Takaaki and Asama, Hiroyuki and Tsumura, Hidetaka and Kamata, Ken and Umemoto, Kumiko and Hamamoto, Yasuo and Suzuki, Yuko and Horiguchi, Shigeru and Naganuma, Atsushi and Asagi, Akinori and Tsuji, Kunihiro and Takada, Ryoji and Kawata, Kazuhito and Kojima, Motohiro and Imaoka, Hiroshi and Terashima, Takeshi and Ozaka, Masato and Ueno, Makoto and Ikeda, Masafumi},
  title = {Multicenter Retrospective Study of Efficacy of Systemic Therapy in Patients with Neuroendocrine Tumor Grade 3 (JOSC-2001)},
  journal = {Neuroendocrinology},
  year = {2025},
  doi = {10.1159/000548614}
}
Kostenlos starten →